Null pattern of immunoreactivity in a lynch syndrome-associated colon cancer due to germline MSH2 mutation and somatic MLH1 hypermethylation

American Journal of Surgical Pathology

Volumn 35, Issue 12, 2011, Pages 1902-1905

  Hagen, Catherine E ^a   Lefferts, Joel ^a   Hornick, Jason L ^b   Srivastava, Amitabh ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

colon cancer; HNPCC; immunohistochemistry; lynch syndrome; microsatellite instability

Indexed keywords

MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AGED; ARTICLE; BIOSYNTHESIS; CASE REPORT; DNA METHYLATION; FEMALE; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PEDIGREE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PEDIGREE;

EID: 81255214998     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318237c6ab     Document Type: Article

References (19)

1. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a lowcost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004;41:664-668. (Pubitemid 39208606)
2. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009; 11:35-41.
3. Grady WM, Aajput A, Lutterbaugh JD, et al. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 2001;61:900-902. (Pubitemid 32174399)
4. Halvarsson B, Lindblom A, Rambech E, et al. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer. Fam Cancer. 2006;5:353-358. (Pubitemid 44924111)
5. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783-5788.
6. Hitchins M, Williams R, Cheong K, et al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology. 2005;129:1392-1399. (Pubitemid 41597381)
7. Jarry A, Masson D, Cassagnau E, et al. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes. 2004;18:349-352. (Pubitemid 39061042)
8. Jass JR. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer. 2004; 3:93-100. (Pubitemid 40645890)
9. Kakar S, Burgart LJ, Thibodeau SN, et al. Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age. Cancer. 2003;97:1421-1427. (Pubitemid 36297771)
10. Lehmann U. Re: Rahner, et al. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol. 2008;214:10-16.
11. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919-932. (Pubitemid 36298000)
12. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76:1-18.
13. Morak M, Schackert HK, Rahner N, et al. Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC. Eur J Hum Genet. 2008;16:804-811. (Pubitemid 351865678)
14. Radu OM, Nikiforova MN, Farkas LM, et al. Challenging cases encountered in colorectal cancer screening for Lynch syndrome reveal novel findings: nucleolar MSH6 staining and impact of prior chemoradiation therapy. Hum Pathol. 2011;42:1247-1258.
15. Rahner N, Friedrichs N, Steinke V, et al. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol. 2008;214:10-16.
16. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293-300. (Pubitemid 352019113)
17. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as firstline screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009;33:1639-1645.
18. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet. 2004;36: 497-501. (Pubitemid 38620035)
19. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. 2008;10:301-307. (Pubitemid 352019114)